CR7059A - USO DE AGONISTAS INVERSOS DE GABAa EN COMBINACION CON AGONISTAS PARCIALES DEL RECEPTOR DE NICOTINA, ESTROGENOS, MODULADORES SELECTIVOS DE ESTROGENOS O VITAMINA E PARA EL TRAMIENTO DE TRASTORNOS COGNITIVOS - Google Patents
USO DE AGONISTAS INVERSOS DE GABAa EN COMBINACION CON AGONISTAS PARCIALES DEL RECEPTOR DE NICOTINA, ESTROGENOS, MODULADORES SELECTIVOS DE ESTROGENOS O VITAMINA E PARA EL TRAMIENTO DE TRASTORNOS COGNITIVOSInfo
- Publication number
- CR7059A CR7059A CR7059A CR7059A CR7059A CR 7059 A CR7059 A CR 7059A CR 7059 A CR7059 A CR 7059A CR 7059 A CR7059 A CR 7059A CR 7059 A CR7059 A CR 7059A
- Authority
- CR
- Costa Rica
- Prior art keywords
- strogens
- vitamin
- agonists
- disease
- difference
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE ENFERMEDADES DE DISFUNCION COGNITIVA EN UN MAMIFERO, QUE COMPRENDE LA ADMINISTRACION DE UN AGONISTA INVERSO DE GABBAa O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, Y UN AGONISTA PARCIAL DEL RECEPTOR DE NICOTINA, UN AGENTE ESTROGENICO, UN MODULADOR SELECTIVO DEL RECEPTOR DE ESTROGENOS O VITAMINA E, O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LOS MISMOS Y UN VEHICULO FARMACEUTICAMENTE ACEPTABLE. EL AGONISTA INVERSO DE GABBAa Y EL AGONISTA PARCIAL DEL RECEPTOR DE LA NICOTINA, LOS ESTROGENOS O LA VITAMINA E ESTAN PRESENTES EN CANTIDADES QUE HACEN QUE LA COMPOSICION SEA EFICAZ PARA POTENCIAR LA COGNICION O EL TRATAMIENTO DE ENFERMEDADES DE DISFUNCION COGNITIVA INCLUYENDO, PERO SIN LIMITACION, LA ENFERMEDAD DE ALZHEIMER (AD), DETERIORO COGNITIVO LEVE, REDUCCION COGNITIVA RELACIONADA CON LA EDAD, DEMENCIA VASCULAR, ENFERMEDAD DE PARKINSON, ENFERMEDAD DE HUNTINGTON, PERDIDA DE MEMORIA ASOCIADA CON LA DEPRESION O LA ANSIEDAD, ESQUISOFRENIA, Y SINDROME DE DOWN.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27256601P | 2001-03-01 | 2001-03-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR7059A true CR7059A (es) | 2004-03-10 |
Family
ID=23040351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR7059A CR7059A (es) | 2001-03-01 | 2003-08-25 | USO DE AGONISTAS INVERSOS DE GABAa EN COMBINACION CON AGONISTAS PARCIALES DEL RECEPTOR DE NICOTINA, ESTROGENOS, MODULADORES SELECTIVOS DE ESTROGENOS O VITAMINA E PARA EL TRAMIENTO DE TRASTORNOS COGNITIVOS |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US20020193360A1 (es) |
| EP (1) | EP1363606A1 (es) |
| JP (1) | JP2004527500A (es) |
| KR (1) | KR20030076717A (es) |
| CN (1) | CN1494422A (es) |
| AP (1) | AP2002002465A0 (es) |
| AR (1) | AR033425A1 (es) |
| BG (1) | BG108131A (es) |
| BR (1) | BR0207802A (es) |
| CA (1) | CA2439581A1 (es) |
| CR (1) | CR7059A (es) |
| CZ (1) | CZ20032338A3 (es) |
| DO (1) | DOP2002000345A (es) |
| EA (1) | EA200300854A1 (es) |
| EC (1) | ECSP034759A (es) |
| EE (1) | EE200300422A (es) |
| GT (1) | GT200200039A (es) |
| HU (1) | HUP0303448A3 (es) |
| IL (1) | IL157465A0 (es) |
| IS (1) | IS6905A (es) |
| MA (1) | MA26999A1 (es) |
| MX (1) | MXPA03007834A (es) |
| NO (1) | NO20033821L (es) |
| NZ (1) | NZ527397A (es) |
| OA (1) | OA12554A (es) |
| PA (1) | PA8540701A1 (es) |
| PE (1) | PE20020927A1 (es) |
| PL (1) | PL364081A1 (es) |
| SK (1) | SK10752003A3 (es) |
| TN (1) | TNSN02018A1 (es) |
| UY (1) | UY27188A1 (es) |
| WO (1) | WO2002069948A1 (es) |
| ZA (1) | ZA200306193B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050065205A1 (en) * | 2002-03-07 | 2005-03-24 | Daniel Alkon | Methods for Alzheimer's disease treatment and cognitive enhance |
| US20080004332A1 (en) * | 2002-03-07 | 2008-01-03 | Alkon Daniel L | Methods for alzheimer's disease treatment and cognitive enhancement |
| US6825229B2 (en) | 2002-03-07 | 2004-11-30 | Blanchette Rockefeller Neurosciences Institute | Methods for Alzheimer's Disease treatment and cognitive enhancement |
| US8030300B2 (en) | 2003-06-10 | 2011-10-04 | Georgetown University | Ligands for nicotinic acetylcholine receptors, and methods of making and using them |
| TW201207390A (en) | 2004-05-18 | 2012-02-16 | Brni Neurosciences Inst | Method for screening agent for antidepressant activity |
| EP1924712B1 (en) * | 2005-08-03 | 2018-10-03 | The Johns Hopkins University | Methods for characterizing and treating cognitive impairment in aging and disease |
| US8510055B2 (en) | 2005-08-03 | 2013-08-13 | The Johns Hopkins University | Methods for characterizing and treating cognitive impairment in aging and disease |
| ES2573733T3 (es) | 2006-05-22 | 2016-06-09 | The Board Of Trustees Of The Leland Stanford Junior University | Tratamiento farmacológico del deterioro cognitivo |
| PL2074123T3 (pl) | 2006-10-16 | 2013-04-30 | Bionomics Ltd | Nowe związki o działaniu przeciwlękowym |
| US10954231B2 (en) | 2006-10-16 | 2021-03-23 | Bionomics Limited | Anxiolytic compounds |
| AU2013202426B2 (en) * | 2006-10-16 | 2015-08-06 | Bionomics Limited | Novel anxiolytic compounds |
| CN101848726A (zh) | 2007-02-09 | 2010-09-29 | 布朗歇特洛克菲勒神经科学研究所 | 苔藓抑素、苔藓抑素类似物和其它相关物质对头部创伤引起的记忆缺陷和脑损伤的疗效 |
| WO2009143347A2 (en) * | 2008-05-22 | 2009-11-26 | Teva Pharmaceutical Industries Ltd. | Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate |
| US20090318695A1 (en) * | 2008-06-19 | 2009-12-24 | Vinod Kumar Kansal | Processes for the preparation of varenicline and intermediates thereof |
| US20100010221A1 (en) * | 2008-07-10 | 2010-01-14 | Revital Lifshitz-Liron | Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt |
| US10206921B2 (en) * | 2009-06-03 | 2019-02-19 | The Regents Of The University Of California | Methods and compositions for treating a subject for central nervous system (CNS) injury |
| EP2438054A1 (en) * | 2009-06-22 | 2012-04-11 | Teva Pharmaceutical Industries Ltd. | Solid states forms of varenicline salts and processes for preparation thereof |
| MX346185B (es) | 2010-11-15 | 2017-03-10 | Agenebio Inc | Derivados de piridazina, composiciones y metodos para tratar deterioro cognitivo. |
| US20140051701A1 (en) * | 2011-03-02 | 2014-02-20 | Bionomics Limited | Methods of treating a disease or condition of the central nervous system |
| AU2012222874B2 (en) | 2011-03-02 | 2015-04-16 | Bionomics Limited | Novel small-molecules as therapeutics |
| CN103649086A (zh) | 2011-05-12 | 2014-03-19 | 生态学有限公司 | 制备萘啶的方法 |
| US10329301B2 (en) | 2013-12-20 | 2019-06-25 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| US10815242B2 (en) | 2015-06-19 | 2020-10-27 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| US11505555B2 (en) | 2016-12-19 | 2022-11-22 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| WO2019246300A1 (en) | 2018-06-19 | 2019-12-26 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| CN116008442B (zh) * | 2023-03-27 | 2023-06-30 | 上海赛默罗生物科技有限公司 | α5-GABAA受体调节剂的合成中间体的杂质检测方法 |
| CN116077459B (zh) * | 2023-04-10 | 2023-07-07 | 上海赛默罗生物科技有限公司 | α5-GABAA受体调节剂的胶囊剂及其制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0003258A3 (en) * | 1997-08-25 | 2001-05-28 | Neurogen Corp Branford | Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands |
| US6448246B1 (en) * | 1999-05-25 | 2002-09-10 | Neurogen Corporation | Substituted 4H-1,4-benzothiazine-2-carboxamide: GABA brain receptor ligands |
-
2002
- 2002-02-20 OA OA1200300213A patent/OA12554A/en unknown
- 2002-02-20 EP EP02700509A patent/EP1363606A1/en not_active Withdrawn
- 2002-02-20 MX MXPA03007834A patent/MXPA03007834A/es unknown
- 2002-02-20 BR BR0207802-3A patent/BR0207802A/pt not_active IP Right Cessation
- 2002-02-20 SK SK1075-2003A patent/SK10752003A3/sk not_active Application Discontinuation
- 2002-02-20 KR KR10-2003-7011366A patent/KR20030076717A/ko not_active Application Discontinuation
- 2002-02-20 CZ CZ20032338A patent/CZ20032338A3/cs unknown
- 2002-02-20 PL PL02364081A patent/PL364081A1/xx not_active Application Discontinuation
- 2002-02-20 JP JP2002569125A patent/JP2004527500A/ja active Pending
- 2002-02-20 WO PCT/IB2002/000515 patent/WO2002069948A1/en not_active Application Discontinuation
- 2002-02-20 EE EEP200300422A patent/EE200300422A/xx unknown
- 2002-02-20 HU HU0303448A patent/HUP0303448A3/hu unknown
- 2002-02-20 CN CNA028058046A patent/CN1494422A/zh active Pending
- 2002-02-20 CA CA002439581A patent/CA2439581A1/en not_active Abandoned
- 2002-02-20 IL IL15746502A patent/IL157465A0/xx unknown
- 2002-02-20 NZ NZ527397A patent/NZ527397A/en unknown
- 2002-02-20 EA EA200300854A patent/EA200300854A1/ru unknown
- 2002-02-26 US US10/083,743 patent/US20020193360A1/en not_active Abandoned
- 2002-02-26 DO DO2002000345A patent/DOP2002000345A/es unknown
- 2002-02-26 PE PE2002000157A patent/PE20020927A1/es not_active Application Discontinuation
- 2002-02-27 GT GT200200039A patent/GT200200039A/es unknown
- 2002-02-27 UY UY27188A patent/UY27188A1/es not_active Application Discontinuation
- 2002-02-27 AR ARP020100693A patent/AR033425A1/es not_active Application Discontinuation
- 2002-02-28 PA PA20028540701A patent/PA8540701A1/es unknown
- 2002-02-28 TN TNTNSN02018A patent/TNSN02018A1/fr unknown
- 2002-02-28 AP APAP/P/2002/002465A patent/AP2002002465A0/en unknown
-
2003
- 2003-08-07 IS IS6905A patent/IS6905A/is unknown
- 2003-08-11 ZA ZA200306193A patent/ZA200306193B/en unknown
- 2003-08-19 MA MA27286A patent/MA26999A1/fr unknown
- 2003-08-25 BG BG108131A patent/BG108131A/xx unknown
- 2003-08-25 CR CR7059A patent/CR7059A/es not_active Application Discontinuation
- 2003-08-28 NO NO20033821A patent/NO20033821L/no not_active Application Discontinuation
- 2003-09-01 EC EC2003004759A patent/ECSP034759A/es unknown
- 2003-12-02 US US10/727,934 patent/US20040082555A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR7059A (es) | USO DE AGONISTAS INVERSOS DE GABAa EN COMBINACION CON AGONISTAS PARCIALES DEL RECEPTOR DE NICOTINA, ESTROGENOS, MODULADORES SELECTIVOS DE ESTROGENOS O VITAMINA E PARA EL TRAMIENTO DE TRASTORNOS COGNITIVOS | |
| SV2002000440A (es) | Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfuncion cognitiva en un mamifero ref. pc10869/20160/bb | |
| CY1106160T1 (el) | Mεταβολιτες βουπροπιονης και μεθοδοι συνθεσης και χρησεις τους | |
| EE200300033A (et) | Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon | |
| AR028505A1 (es) | Utilizacion de un antagonista de los receptores de cannabinoides centrales para la preparacion de medicamentos utiles para que sea mas frcil detener el consumo de tabaco | |
| DK1404331T3 (da) | Sustained release-formuleringer af oxymorphon | |
| NO20070578L (no) | Oral doseringsform sikret mot misbruk inneholdende (1,2R)-3-(3-dimetylammino-l-etyl-2-metyl-propyl)-fenol | |
| UY25067A1 (es) | Acetato de sertralina, composiciones farmacéuticas que lo contienen y procedimientos de preparación. | |
| HN2002000275A (es) | Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados | |
| WO2000051546A3 (en) | Bupropion metabolites and methods of their synthesis and use | |
| ES2151672T3 (es) | Composiciones de rapida disolucion oral para agonistas de dopamina. | |
| HK1113970A1 (en) | Formulations for injection of catecholic butanes, including ndga compounds, into animals | |
| BR9509807A (pt) | Composição líquida para administração oral e processo para tratar um mamífero incluindo o homem que esteja sofrendo de um quadro clinico mediado pela aç o do 5ht nos receptores 5ht3 | |
| GT200300294A (es) | Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso | |
| UY27023A1 (es) | Derivados de fenil cetonas sustituidas como antagonistas de ip | |
| ES2190205T3 (es) | Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda. | |
| UY25356A1 (es) | Polisacaridos de sintesis,procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
| ES2174337T3 (es) | Uso topico de los agonistas opioides kappa para el tratamiento del dolor ocular. | |
| CR6581A (es) | Pirrolcarboxamidas fundido, receptores cerebrales gaba | |
| AR029588A1 (es) | Nueva forma (r)-n-[5-metil-8-(4-metilpiperazina-1-il)-1,2,3,4-tetrahidro-2-naftil]-4-morfolinobenzamida | |
| EA200100828A1 (ru) | 16-гидроксиэстратриены в качестве эстрогенов избирательного действия | |
| MXPA03001610A (es) | Derivados de acido oxazolil-arilpropionico y su uso como agonistas de los receptores activados por proliferadores de peroxisomas. | |
| DE69917005D1 (de) | Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung | |
| BR0314540A (pt) | Métodos para o tratamento de neurodegeneração | |
| TR200101090T2 (tr) | Sertralin ağız konsantratı |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal (granting procedure) |